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We provide a brief review of research on chronic kidney disease and cognitive performance,
including dementia. We touch briefly on the literature relating end-stage-renal disease to cognitive
function, but focus on studies of modest and moderate forms of chronic kidney disease (CKD) that
precede dialysis and transplantation. We summarize previous reviews dealing with case control
studies of patients but more fully examine community-based studies with large samples and
necessary controls for demographic risk factors, cardiovascular variables, and other confounds
such as depression.
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In addition we suggest potential biological and social-psychological mediators between CKD and
cognition. Studies follow in two categories of design: (1) cross-sectional studies; (2) longitudinal
studies. In each, CKD is related to a wide range of deficits in cognitive functioning including,
verbal and visual-memory and organization, and components of executive functioning and fluid
intellect. In general, prior to the need to treat with hemodialysis (HD) or kidney transplant (KT),
magnitude of effect with relation to CKD and function are small or modest in persons free from
acute stroke and dementia. However, HD and KT can result in major impairment. We discuss
needed controls, the greater demand on controls after HD and KT begin, and suggest that
mechanisms intervening relations between hypertension, or diabetes, and cognitive performance
may be similar to those intervening between hypertension and cognitive performance and the
hypertension and diabetes literature on cognition provides a good model for the study of early
stage kidney disease and cognitive ability. We posit that the mechanisms linking CKD and
cognition may be similar to those linking hypertension or diabetes to cognition.
We identify the need for more studies with multiple cognitive test batteries, measures of every-day
cognitive abilities relevant to patient understanding of the disease and treatments, and more
studies with prevalent and incident dementia outcomes.

Descriptors
kidney disease; chronic kidney disease; cognitive function; dementia; cardiovascular risk factors
A new case of dementia occurs every four seconds world-wide, which is equivalent to 7.7
million cases each year, and mild cognitive impairment is even more prevalent [1]. Chronic
kidney disease (CKD) is a risk factor (RF) for dementia and cognitive impairment [2, 3–5].
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Cognitive impairment detracts from quality of life and is a risk factor for dialysis-related
mortality [6]. In this brief review we summarize the literature on CKD in relation to
cognitive function, discuss intervening mechanisms, and comment on some methodological
issues, but refer the reader to other reviews of the many studies comparing treatments such
as hemodialysis (HD), peritoneal dialysis (PD) and transplantation. We emphasize a pretreatment stage of CKD, but include studies examining modest to severe CKD.

Renal Functioning Predictors of Cognitive Function
Renal disease is well-defined in previous reviews [2,3–5,7]. Table 1 summarizes commonly
used predictor variables in cognitive studies and the measurement metrics used to define
them. Common predictors are estimated glomerular filtration rate (eGFR), serum creatinine
(sCR) and far less commonly stages of renal disease [2] involving measures such a
proteinuria, biopsy or structural imaging.

Cognitive Outcomes in Renal Studies
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A previous review provides a list of tests commonly used in the renal literature [3] and other
reviews illustrate how multiple tests should be used where the goal is to infer the locus of
brain impairment from one or more specific cognitive deficits [8,9]. Studies designed to
examine which abilities do and do not relate to a disease must examine a wide range of
different abilities [8,9]. Definitions of terms used in the psychometric literature are given in
Table 2. Outcome variables can be dichotomous (i.e., dementia, impairment, deficit), ordinal
categories of performance level, or continuously distributed test scores representing
performance level. We use the term cognitive impairment only if this cognitive status has
been established by clinical criteria, i.e., neuropsychological (NP) evaluation and/or
normative data. The term deficit is used as a comparative term indicating a lower average
level of performance relative to a reference group or groups. The term decline is only used
for longitudinal change in performance.

Overview: End Stage Renal Disease (ESRD) and Treatment
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We refer to the reader to previous reviews [2,3–5] for a summary of this literature. However,
it is important to note that an estimated 70% of hemodialysis (HD) patients over age 55
exhibit moderate to severe cognitive impairment [5] with a similar prevalence for peritoneal
dialysis (PD) patients [10]. Griva et al. [6] reported that two-thirds of a community-dwelling
sample of 145 PD, home-dialysis and in-center HD patients in London, UK suffered from
what the authors defined as mild or moderate cognitive impairment: 1.00–1.99 and 2–2.99
SD below the mean, respectively. We agree with Murray and Knopman [5] that performance
2.00 SD below the mean (3% of the population fall here) is not moderate, but is reflective of
clinically significant cognitive dysfunction. Comprehensive reviews of this literature
indicate that HD, PD and transplantation are associated with wide ranging deficits in
attention, memory, speed of performance, and components of executive functioning (EF)
[4,5], although it is clear that adverse cognitive outcomes are attenuated when cognitive
testing is timed properly in relation to dialysis treatment [2].
There have been few studies of practical every-day cognitive tasks and kidney disease.
Numeracy skills are critical to advance planning necessary to comply with treatment
regimens and disease understanding [11]. Numeracy refers to the degree that one can apply
statistical, graphical and numerical skills in such a way as to effectively understand and
comply with health information [11]. Abdel-Kader et al. [11] found that the majority of 187
ESRD patients (mean age=52 years) exhibited low numeric efficiency on a 3-item scale.
Grubbs et al. [12] reported a 32.3% prevalence of inadequate health care literacy in a sample
of 62 dialysis patients. Gelb and colleagues [13], in a study of 108 kidney transplant
Contrib Nephrol. Author manuscript; available in PMC 2014 May 03.
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recipients, reported that lower levels of performance on every-day problem solving tests and
number of depressive symptoms were associated with poor medication adherence, but found
no association with multiple NP measures and adherence. These studies were not
prospective and thus the direction of these associations needs to be defined in future studies.
In summary, the history of cognitive deficit and impairment begins prior to the transition to
ESRD [5]. Once ESRD status has been reached and dialysis has begun, the demands on
design and control become increasingly complex and thus the early or pre-treatment stages
of CKD provide an important window of investigation.

Cross-Sectional Community-Based Studies
We have chosen to focus on the community-based studies given the very much larger
samples, statistical adjustment for CVD and absence of sample bias introduced by multiple
exclusions in order control for differences in health factors among uremic samples, healthy
controls and patient groups.
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Table 5 summarizes methodological detail and results for the community-based studies
which began to appear in 2005. Earlier investigations emphasized case-control type studies
that compared uremic patients to other diagnostic groups, e.g., medical and psychiatric
patients or healthy controls [2]. A major review of this case-control literature[2] indicates
that uremic patients, compared to general medical and psychiatric groups, performed better
on measures of motor speed, auditory alertness and crystallized intelligence and performed
more poorly on measures of cognitive flexibility and other components of EF, verbal
memory and learning, visual attention and fluid intelligence. In 3 of the case-control studies
reviewed by Koushik et al. [2], levels of performance were not below average when
compared to normative data. In some case-control studies exclusion for health factors were
extensive, e.g. [14], but often the major controls were for age, education, and sex [2].
In each of the community-based studies (Table 3) there were controls (exclusion or
adjustment) for demographic variables, CVD risk factors, or health factors, and other
confounders. Estimated eGFR levels <60, versus ≥60 were associated with deficits in global
cognitive performance. Studies prior to 2009 reported that higher levels of eGFR were
associated with deficits in language, memory, components of EF [15,16], learning and
concentration [15], visual attention [15], psychomotor efficiency and processing speed [17],
and global impairment on a telephone interview scale [18]. While sample sizes were
impressive, the cognitive batteries were limited, sometimes involving only one or a few
tests.
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To address this issue, Elias et al. [19] using the Maine Syracuse Longitudinal Study
(MSLS), employed 923 dementia-free community-dwelling individuals and 19 widely-used
clinical cognitive tests in a factor analysis leading to the identification of the following
outcome variables: (1) a global composite test score; (2) four composite scores or factors:
visual-spatial organization and memory, scanning and tracking (a component of executive
function), verbal memory, and working memory and (3) a single measure of abstract
reasoning (WAIS Similarities) which loaded with approximately equal strength on each
composite. Persons undergoing dialysis (n=4) and/or diagnosed with dementia (n=9) were
excluded. For an analysis adjusting for demographic factors, CVD, and acute stroke, higher
sCR values were associated with lower levels of performance for global performance, verbal
episodic memory and scanning and tracking. For example increments in creatinine of 2 mg/
dL were associated with a decrement of 0.12 SD in performance level. Moreover, the odds
ratios (ORs) associated with poor global performance (defined as the lowest quartile of the
distribution of test scores) were OR=2.27 with control for age, sex, education, and race and
OR=1.97 with additional adjustment for CVD and stroke.
Contrib Nephrol. Author manuscript; available in PMC 2014 May 03.
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In summary, community-based, large sample, cross-sectional studies support the
generalization that mild and modest kidney disease is related to modest deficits in multiple
cognitive abilities. As in the hypertension literature, crystallized intellect appears to be
spared in studies of dementia-free samples [19]. The limitation of each of these studies is
that they were cross-sectional and only two studies specifically reported excluding of
dialysis patients [19,20] or those with eGFR<30 [15].

Longitudinal Studies
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Longitudinal studies of community-based samples after 2004 are summarized in Table 4.
These studies measure change in cognitive functioning over time. Studies are arranged by
outcomes: (1) level of cognitive performance, (2) binary levels of performance where
decline in performance is based on poor performance at followup defined arbitrarily or in
terms of normative data; (3) binary or gradations of certainty with regard to probable
dementia. The first two categories are important to the third because lower cognitive
performance in persons free from acute stroke and dementia is a risk factor for dementia
[21]. The studies cited have relatively good controls as defined by adjustment for age, sex,
education, and race, where relevant, and extended models which consider health variables,
cardiovascular risk factors or events (e.g. stroke). Table 5 provides a check-list summary of
results for papers summarized in Table 4. Each of the studies [20,22–28, Note 1] reported
that baseline levels for at least one predictor was related to cognitive decline, impairment or
dementia, except for Slinin et al. [29] who obtained negative results with adjustment for age.
Davey et al. [Note 1] with the smallest longitudinal sample (N= 590), but with a
comprehensive cognitive test battery, did not find longitudinal change in cognitive
performance from baseline to followup. However, a decline in renal function over time
(indicated by eGFR or sCR) was related to decline in global cognitive performance, verbal
memory and abstract reasoning. Negative findings relative to decline in cognitive
performance relative to baseline levels of renal function are not readily explained by study
length or number of cognitive measures. Relative to other studies, Davey et al. [Note 1]
featured the largest number of cognitive outcomes and a fairly long followup of 4 to 5 years.
But the sample was relatively well-educated and change in renal function may be more
sensitive in terms of cognitive change than baseline levels. Following 2406 participants over
4 years, Helmer et al. [23] also found that change in renal function over 4 years but not
baseline renal function was related to longitudinal decline (incident dementia).
None of the longitudinal studies used an every-day measure of cognitive performance or
employed numeracy as a predictor or covariate and only 5 of the 16 studies summarized in
Tables 4 and 5 adjusted for clinical depression or depressed mood.
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Obviously there is a need for more studies with comprehensive test batteries, longer
longitudinal followup periods and stratification by education level and/or numeracy skill,
and with explicit exclusion of renal dialysis patients. Yet considering these studies
collectively, it is clear that depending on severity of renal disease and the general health of
the study population, various indices of CKD prevalence are related to decline in cognitive
performance over time and dementia in samples over 65 years of age. What is not known
from current studies is the prevalence, incidence or rate of cognitive decline prior to
dementia.

Note 1Davey, A, Elias, MF, Robbins, A, Seliger, SL, Dore GA. Decrease in renal functioning is associated with longitudinal decline
in global cognitive functioning, abstract reasoning, and verbal memory. Unpublished Manuscript, Submitted to Nephrol Dial
Transplant, revised and under re-review.
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It is encouraging to find that in the study of relatively well-educated non-demented
community-based subjects, dialysis excluded, decline in performance levels over 4 to 5
years was modest and not such that they would interfere with understanding and adherence
necessary to the treatment of renal disease [Note 1].

Mechanisms Relating Kidney Disease to Cognition
Table 6 lists variables that may mediate between renal disease and cognitive function. One
may hypothesize, among other models, direct paths in which CKD affects brain function and
morphology and hence cognition. An alternative, and not mutually exclusive, possibility is
that risk factors shared by brain and kidney lead to cognitive deficit, decline and impairment
[30]. This parallel risk factor model is appealing because “both kidney and brain are low
resistance end-organs and are exposed and re-exposed to high-volume blood flow though the
cardiac cycle” [30 p.5]. Thus the brain and kidney very likely share common risk factors for
cognitive deficit and impairment. It is clear that the issue of mediating variables becomes
complex once treatment is initiated for ESRD. Thus we refer the reader to a comprehensive
model by Murray & Knopman [5] and in Table 6 summarize the many candidate
mechanisms. In pre-treatment forms of renal disease it makes some sense that the search for
mechanisms should begin with the strongest risk factors for kidney disease, i.e.,
hypertension and diabetes. However, few if any mediation studies have been undertaken.

NIH-PA Author Manuscript

Methodological Issues
Controls
Controls for age, education, sex, and where relevant, race and ethnic composition are
imperative, and controls for prevalent CVD risk factors, including depressed mood or
clinical depression, and CVD events (e.g. acute stroke) are very important. But inspection of
Table 6 indicates that many other potential confounders exist even where the focus is preESRD kidney disease. Polypharmacy is highly prevalent in the elderly. Moreover, many
social psychological factors that are correlated with renal disease are especially important
when patient groups or non-patients are employed as control groups.
Cognitive Measurement
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The finding that renal disease is related to multiple cognitive abilities, with few exceptions
(e.g. over-learned crystallized intelligence), may be related to the fact that renal disease has
a diffuse effect on brain function. However, it is important to recognize that the clinical
cognitive tests traditionally employed in research on disease are impure, i.e., they measure a
mixture of intended and untended cognitive constructs. Clinical cognitive tests are highly
correlated with each other and with tests of general intellectual functioning [9]. There are
two solutions: (1) factor analyses that identify theoretically-relevant cognitive domains, e.g.
[19], and (2) utilization of more precise information processing tasks [9]. The latter method
increases measurement purity but also increases performance difficulty for poorly educated
study participants, makes significant demands on study time, and is less clinically
interpretable.

Clinical Implications
In general, pre-dialysis and pre-transplant levels of cognitive deficit are relatively modest in
well cared for and relatively highly educated, dementia- and stroke-free community samples,
e.g., [19,22]. This is good news and suggests that intervention might possibly be effective in
preventing or delaying more serious ESRD and ESRD-treatment related cognitive deficit
and impairment [4,5]. This conclusion is tentative pending more studies and clinical trials.

Contrib Nephrol. Author manuscript; available in PMC 2014 May 03.
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Prior to ESRD and treatment, kidney disease can result in global and multiple, specificcognitive deficits, often mild, but sometimes associated with dementia. Treatment methods
are improving but the physiological consequences of treatment can lead to more severe
deficit. Biological factors intrinsic to renal disease, psychosocial factors, and polypharmacy
are candidate intervening mechanisms, but formal studies identifying mediators between
mild and modest levels of kidney disease and cognition have not been done.
We are starting down the path of a complex and challenging area of research and have a
long way to go. We are in a descriptive phase of research, albeit we need more studies with
comprehensive batteries of cognitive tests and tests of every-day cognitive function. To our
knowledge, there have been no randomized-to-treatment clinical trials addressing
improvement in cognitive performance with treatment for CVD risk factors. The clinical
trial literature on hypertension provides a good model for this important next step.
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Definitions of terms used in this review.
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Tern

Definition

Construct

The theoretical mental process that tests attempt to measure or index.

Decline

Change in performance level from better to worse over time.

Deficit

A relative decrement in performance that does not rise to the level of impairment, e.g. mean level of
performance in a group is lower than mean level of performance in another group, but individual differences in
performance may overlap among groups.

Dementia

A progressive cognitive impairment characterized by decline in memory ability and impairment in one or more
other cognitive domains, e.g., language, orientation, reasoning, attention and executive functioning (EF).
Represents a decline from a previous level of functioning and interferes with activities of daily living and
independence. Alzheimer’s Disease (AD) is the most common form and a major risk factor is amnestic MCI.

Domain

A composite set of skills measured (indexed) by more than one test of specific ability as may be identified by
factor analysis.

Every-Day ability

A test that measures real-life activities such as map reading, check balancing, following directions, organizing
medications.

Executive Function

The ability to anticipate, plan and organize and to reject old inappropriate responses for new appropriate
responses when confronted with a new problem. Difficult to separate from fluid intelligence and often and
erroneously used as isomorphic with frontal lobe function, although frontal lobe damage is associated with
poorer EF.

Fluid Intelligence

Ability with regard to dealing with new and novel tasks as opposed to crystallized (verbal intelligence) ability,
often with demands on speed of performance. Many reviews of the literature have emphasized the extreme
difficulty of separating fluid intelligence from executive functioning [EF] given their significant overlap in
abilities measured [ref number here]

Global Ability

Overall ability which is the synergistic combination of specific abilities, e.g. overall score on an intelligence test.

Impairment

Poor performance reaching a clinically important level of deficit as defined by neuropsychological assessment
and/or normative data.

Impurity

Failure of a test to measure only abilities it was designed to measure.

Level of Performance

An average or median level of performance based on the entire distribution of test scores or normative data.

Mental Status

Ability measured by screening measures such as the Mini Mental Status Examination (MMSE), often described
as a test of global ability but lacking in sensitivity and specificity relative to intelligence test measures.

Mild Cognitive Impairment

Mild Cognitive Impairment (MCI) is a level of performance that indicates decline from a previous level of
performance and impairment by clinical/normative criteria, but does not rise to the level of dementia.
Individuals with MCI typically remain in the community and do not necessarily exhibit general intellectual
decline. There are at least 30 different definitions formal clinical definitions in the literature.

Short Form

A shorter form of a test designed to retain validity and reliability but normally looses both to some extent.

Specific Ability

Ability in a relatively narrow range of specialized functioning as opposed to global cognitive ability or general
intelligence.

Vascular Dementia (VaD)

Memory decline may be present but not necessarily predominant and other cognitive domains are affected early
in the disease process and in the MCI that precedes it. Progress of VaD is more varied over time than is the
progress of AD and a history of CVD risk factors and events are common. AD has a vascular component and
mixed dementias are common.
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Table 2

Common predictor variables in studies of renal disease and cognitive performance,
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Predictor

Metric or Type of Measurement

Type of Variable

Uremic Patient1 vs Controls

Diagnostic criteria

Categorical

eGFR2

mL/min per 1.73m2 body surface

Categorical4 or continuous.

Serum Creatinine (sCR)

mg/dL or μmol/L

Continuous5

Stage of Kidney Disease3

Standard Diagnostic Criteria

Categorical

1

Uremia defined as the accumulation of urinary waste products in the urine or the constellation of signs and symptoms indicating kidney disease or
failure.

2

eGFR (estimated glomuerular filtration rate) be estimated via different formulae: Modification of Diet in Renal Disease (MDRD) study equation
Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation Mayo Clinic Quadratic equation

3

See reference 5 for definitions and criteria.

4

Studies often use eGFR ≥60 (mL/min/1.73m2) versus <60, or, for example, normal (≥90); mildly decreased (60 to 89); moderate CKD (30–59),
severe CKD (15 to 29) and kidney failure (<15), or clinical criteria, tertiles, quartiles, quintiles etc.

NIH-PA Author Manuscript

5

Continuously distributed such as eGFR in units (ml/min/1,73m2) or sCR in units (1 mg/dL) expressed as 1/sCR due to skew. [see reference 26 as
example].

NIH-PA Author Manuscript
Contrib Nephrol. Author manuscript; available in PMC 2014 May 03.

NIH-PA Author Manuscript
Simple visual-motor
reaction time, visual
attention and learning and
concentration tests.

Multiple cognitive tests with
composite scores measuring
three domains: attention and
working memory;
psychomotor efficiency and
processing speed; learning
efficiency

Younger, healthy and ethnically diverse
community-based adults recruited from the
NHANES III (age range 20–59; N range
4721 to 4865 depending on the test used).
Moderate CKD was defined as eGFR 30 to
59 with eGFR> 60 as the reference group.
99 uremic patients (mean age 65, with 50%>
65 years) with stage 3 to 5 kidney disease on
optimized medical treatment at a pre-dialysis
clinic. Renal function defined as eGFR
calculated as a continuously distributed
variable.

23,405 community – dwelling participants
(>44 years) from the REGARDS Study.
CKD defined as < 60. eGFR in 10- ML/min/
1.73m2 increments.
923 community dwelling participants (> 40
years of age); comparisons between eGFR>
60 and ≤ 60; increment in sCR from 1 to 2
mg/dL, and 1/sCR as a continuously
distributed variable.

Hailpern et al.
(2007)[15]
Level expressed as
quartiles, referent
group is quartile
with the poorest
performance.

Jassal et al. (2008)
[17]
Performance level
(test scores).

Kurella Tamura, et
al. (2008)[18]

Elias et al.1 (2009)
[19]
Performance
decrement defined
as the lowest
quartile and also
performance level
Based on 19 tests submitted
to factor analysis.
Composite scores were
formed for verbal episodic
memory (VEM), visualspatial memory and
organization, (VSOM)
scanning and tracking (ST),
working memory (WM), and
a global composite of all
scores.

A six item telephone
screening test with cognitive
impairment (sic. deficit)
defined as a score of <4.

Multiple tests including
3MS, Trail Making Part B,
Boston Naming, Verbal
Fluency, Word List Memory
and Recall.

1,105 community-dwelling post-menopausal
women (<80 years) with established
coronary artery disease (no hysterectomy)
enrolled in the Estrogen/Progestin
Replacement Study. CKD estimated using
eGFR as mild (45–59), moderate (30–44)
and severe (eGFR< 30); eGFR ≥60 was
referent group.

Kurella et al. (2005)
[16]

Outcomes

Design

Authors

Adjusted for age, education, sex, race,
diabetes, systolic blood pressure, BMI,
smoking, HDL and stroke and other risk
factors in sensitivity analyses.
Exclusions: dialysis, dementia, <40 years
of age.

Excluded eGFR <10. Adjusted for age,
education, sex, race, recruitment location,
CVD and CVD risk factors.

Adjustment for age, education and sex,
comorbid diseases, hemoglobin, PTH,
and number of neurodepressor drugs.
anti-depression medication, parathyroid
diseases. Sensitivity analysis with ESPS.
Exclusions: head injury, learning
disabilities, history of acute stroke and
TIA, and depressed mood.

Ordinal regression analysis, adjustment
for demographic variables and selfreported health variables. Diabetes
excluded in sensitivity analyses.

Adjustment for age, race, education,
lifestyle factors, stroke, diabetes, and
other variables related to kidney disease.

Control or Adjustment
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Community-based studies published after 2004 arranged by date of publication.

Comparisons of persons with eGFR ≥ 60 with
eGFR< 60 indicated decrement for the latter
group for the global composite, OR= 1.25,
VSOM, OR= 1.88), and ST (components of EF),
OR= 1.56. Same associations for performance
level outcomes.
Higher levels of creatinine were associated with
lower levels of performance on the global
composite, WM, and ST.

CKD<60 was associated with higher risk of
cognitive deficit (OR= 1.23). Each 1-mL/min
1.73m2 was associated with an increment in
cognitive impairment (OR=1.11).

Renal function (eGFR) was related to poorer
performance on test of psychomotor efficiency
and processing speed with statistical adjustment
for covariates, but was not associated with
performance scores for attention and working
memory or learning ability.

Moderate CKD was associated with poorer
learning and concentration (OR= 2.4) and visual
attention (OR= 2.7) when adjusted for age,
gender, education, race, and self- reported
general health and other variables related to
CKD.

eGFR was associated with deficits in global
cognition, executive function, language, and
memory (15 to 25% increment in risk for deficit
per 10 mL/min/1.73m2 decrement in eGFR.

Summary of Findings
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Predictor(s)
Continuous eGFR
(MDRD) at baseline and
trichotomized impaired
kidney function at baseline
defined as <45, >45 to
<60, > 60.

eGFR categorized as ≥60
or <60 and albuminuria
(ACR ≥30 mg/g) versus
no- albuminuria.

Categories of eGFR: ≥90
(reference), 60–89, 30–59;
continuous eGFR in
secondary analyses;
albuminuria defined as ≥
25 mg/g for males and ≥
17 mg/g for females.
Continuously distributed
eGFR and 1/sCR and
change in eGFR baseline
to followup.

Categories of eGFR: ≥60
(reference), 45- 59, <45.
Also used estimated
creatinine clearance
(Cockroft-Gault) and
gender-specific creatinine
cut-points (top 1 and 10
percent of distributions).

Authors, Outcome and
Time to Followup

Buchman et al. (2009)[22]
Decline in performance
over 3.4 years.

Jassal et al. (2010)[24]
Annual decline in
performance level over
mean follow- up of 6.6
years.

Wang et al. (2010)[28]
Decline in performance
over 4 years.
(yes/no) in relation to
baseline eGFR.

Davey et al. [Note 1]
Decline in level of
performance (over 4–5
years).

Kurella et al. (2005)[25]
Incident impairment (yes/
no) with followup at 2 and
4 years.
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Basic: age, race, gender, education
Additional: baseline CVD,
diabetes, BP, lipids, inflammatory
markers, hematocrit concentration,
incident stroke
Exclusions: baseline cognitive
impairment; ADL difficulties; lifethreatening illness; intention of
moving before follow-up

Basic controls: age, education, sex
race/ethnicity, eGFR at baseline.
Additional controls: diabetes,
depressed mood, alcohol
consumption, diabetes and
hypertension, APOE genotype,
smoking, and cardiovascular
disease.
Exclusions, stroke at baseline
dementia and renal dialysis.

Basic: age, sex, education, BMI
Additional: SBP, diabetes, urinary
ACR.
Exclusions: stroke

Stratified by sex.
Covariates: age, SBP, HbA1C,
education, strenuous exercise,
alcohol consumption, current
estrogen for women, eGFR,
depressed mood, antihypertensive
meds, lipid-lowering meds,
Exclusions: <50 years of age,
stroke

eGFR at baseline, age, sex,
education, BMI, hemoglobin,
physical activity, social activity,
vascular risk factors, vascular
diseases, depressive symptoms.
Exclusions. Dementia

Controls: adjustments or
exclusions

2406 elderly persons in the
Health ABC Study (mean
age = 74 years).

590 Maine- Syracuse
Longitudinal Study
participants who
participated at baseline and
followup.

1,243 community- based
Chinese participants (≥ 40
years of age) with an
eGFR> 30; and 66 cases of
during a 4-year followup.

759 community dwelling
men and women (mean age74.9 years) at baseline who
returned for repeat testing.

886 community- dwelling
participants (mean age=
80.6) from the Rush
Memory and Aging Project
who participated in both
baseline and followup
analyses.

Sample

Modified Mini- Mental
State Exam (3MS) with
incident “impairment”
defined as 3MS <80 or
decline in 3MS >5 at either
followup exam.

Decline in performance
level for abstract reasoning
and 4 major domains of
functioning based on factor
analysis of 19 separate test
scores.

A fall in MMSE of ≥2
points from baseline was
defined as cognitive
decline.

MMSE, Trails B, and
Animals Naming Category
Fluency test performance
levels, both continuous and
using cut points.

5 subscale composites and a
global composite derived
from 19 individual
measures. Subscales were:
episodic memory, semantic
memory, working memory,
perceptual speed,
visuospatial abilities.

Cognitive Tests or
Diagnostic Category

eGFR levels <60 were associated
with greater odds of cognitive
impairment, with adjustment for the
full model. Creatinine levels in the
top 10% and 1% were associated
with higher odds of cognitive
impairment, with adjustment for the
basic model.

Baseline levels of eGFR and 1/sCR
were unrelated to longitudinal
change but change in renal function
(eGFR) longitudinally was
associated with change in cognitive
performance for the global
composite, verbal memory
composite, and Similarities with all
controls employed.

Relative to the reference group, risk
of decline was higher for those with
eGFR of 30–59

For men but not women, baseline
albuminuria, but not eGFR, was
associated with decline in MMSE
and category fluency scores with
adjustment for all covariates.

Lower eGFR and impaired kidney
function associated with rate of
decline in global composite,
episodic memory, semantic
memory, and working memory.

Major statistically significant
findings1

Longitudinal studies of relations between kidney function and cognitive function organized by type of outcome (see italics): levels, impairment, dementia.
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Primary: 1/sCR;
Secondary: Renal
insufficiency: sCR ≥1.3
mg/dl for women and 1.5
mg/dl for men.

eGFR (CKD-EPI) at
baseline and change in
eGFR over time,
proteinuria

CKD present/absent based
on eGFR and albuminuria

Seliger et al. (2004)[27]
Incident dementia (AD &
VaD); followup median 6
years.

Helmer et al. (2011)[23]
Incident dementia (AD,
vascular) and change in
level of performance on the
MMSE; followup median
6.8 yrs.

Sasaki et al. (2011)[26]

Negative results are not summarized (see variables column).

1

Baseline normal (>60)
mild (45–59), and
moderate- severe(<45)
CKD based on eGFR
(Cockroft-Gault
standardized for body
surface area)

Etgen et al. (2009)[20]
Incident impairment over 2
years (yes/no) from in
relation to baseline eGFR.

Incident dementia

eGFR (MDRD)
categories: ≥60
45–59 (mild CKD)
<45 (moderate CKD)

NIH-PA Author Manuscript

Slinin et al. (2008)[29]
Incident impairment (yes/
no) in followup 4.6 years.

Age, sex, education, hypertension,
diabetes, dyslipidemia, ischemic
heart disease, anemia.

Basic: Adjustment for study center,
age, sex, education, APOE
genotype.
Additional: hypertension, CVD,
stroke, high lipid levels, diabetes,
smoking, BMI, baseline eGFR.
Exclusions: prevalent dementia at
baseline

Basic: Adjustment for age, sex,
race and body weight. education,
coronary heart disease, diabetes,
hypertension, smoking status, and
ApoE genotype;
Exclusions: prevalent dementia at
baseline

Basic: age,
sex Additional: depression,
physical activity, alcohol, diabetes,
IHD/stroke, hyperlipidemia,
hypertension, smoking
Exclusions: cognitive impairment
at baseline; CKD at baseline in
secondary analyses.

Basic: age, education, race
Additional: health status, IADL
impairments, alcohol use, diabetes,
hypertension, stroke, CVD, BMI,
PAD
Exclusions: unable to walk;
bilateral hip replacement; severe
medical conditions, dialysis
excluded in secondary analyses

Controls: adjustments or
exclusions

256 community- dwelling
participants from the OsakiTajiri Project (Northern
Japan) (≥ 65 years).

7,839 participants of the 3C
Study (baseline eGFR);
2,382 multiple eGFR 1,040
proteinuria
(Age> 65 yrs).

3349 participants of the
Cardiovascular Health
Cognition Study (age> 64
yrs). Incident dementia=
477 cases.
Stratification by health
status at baseline: poor,
good and excellent

3154 INVADE study
participants (>54 years)
(396 with cognitive
impairment at baseline and
194 with incident cognitive
impairment at followup.:

3722 community- based
men (≥65 years) from the
Osteoporotic Fractures in
Men Study who provided
baseline and followup data.

Sample
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Predictor(s)

Dementia: NINCDSADRDA and NINDSAIREN criteria

Diagnosis of dementia;
based on NP examination
and review by neurologist
(DSM- IV criteria).
Etiology based on
NINCDS-ADRDA and
NINDS-AIREN criteria

Diagnosis of dementia
based on multiple test
scores and clinical review.
Type of dementia assessed
with MRI.

Blessed Information
Memory Concentration
Scale (6CIT). A score > 7
defined as impairment

3MS and Trails B
Impairment defined as an
3MS score< 80 or decline
≥5; or increase in Trails B
time ≥1 SD above mean
change

Cognitive Tests or
Diagnostic Category

Association between CKD and
conversion to dementia from a
normal or questionable state at
baseline with adjustment for all
covariates.

No increased risk of cognitive
decline or incident dementia in
relation to eGFR at baseline.
However, eGFR decline was
associated with decline in global
cognition (MMSE) and eGFR
decline >4/year and proteinuria
were related to increased risk for
incident vascular dementia (with
adjustment for extended covariate
set).

Associations between elevated
creatinine and incident dementia,
but only non-dementia participants
in good to excellent health at
baseline; higher sCR associated
with increased risk of VaD, but not
“pure” AD-type dementia.

eGFR <45 associated with
cognitive impairment with
adjustment for all covariates.
With exclusion of CKD at baseline,
incident CKD (eGFR < 60) was
associated with incident cognitive
impairment (covariates not
reported).

Odds of incident impairment in
relation to CKD was observed but
was attenuated and not significant
with adjustment for age.

Major statistically significant
findings1
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✓

✓

✓

✓

✓

✓

Slinin

Etgen1

Seliger2,3

Helmer

Sasaki

✓

✓

1

1

19

Only for dementia free persons in good or excellent health at baseline.

3

Renal insufficiency, defined differently for men (1.5mg/dl) and women (1.3 mg/dl), was related incident dementia.

2

Based on Cockroft-Gault formula, standardized for body surface area.

1

✓

✓

Kurella

✓

2

✓

✓

✓

Davey

✓

✓
✓

✓

Wang

✓

✓

✓

Dementia

✓

19

Number of Tests
used As
Outcomes

Jassal

✓

Composite of
Tests (Global)

✓

MMSE/3MS (Global)

✓

Albuminuria (Alb)

Buchman

Creatinine

eGFR

First Author

✓

✓ eGFR/sCR

✓ eGFR

✓

✓ eGFR

✓ Alb male

✓ eGFR

Relative to baseline
renal function

✓

✓ eGFR/sCR

Relative to change in
renal function

Decline on any test or Incident Dementia

Summary check sheet for essential methods and findings with eGFR Serum Creatinine, Albuminuria as outcome variables with studies ordered as in
Table 4.
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Some candidate mechanisms mediating between kidney disease and cognitive functioning on order of
discussion in text.1
CVD Risk Factors

Hypertension, chronic hypotension, diabetes mellitus, hyperlipidemia, cardiovascular disease, including myocardial
infarction, arterial fibrillation, cigarette smoking, elevated homocysteine, hemostatic abnormalities,
hypercoagulation, oxidative stress, inflammation, acute stroke,

Biologic Intrinsic

Vascular changes in brain; anemia, white matter lesions, anemia, cortical atrophy, hyperparathyroidism,
microalbuminuria, subclinical atherosclerosis

Psychosocial/Treatment

Clinical depression and depressed mood and other psychosocial variables, polypharmacy, malnutrition,

Dialysis- related

Hypotensive episodes, chronic microembolism, subclinical increases in brain edema, acute stroke, silent and
asymptomatic stroke, hemodynamic changes and fluid shifts, microalbuminuria, recurrent cerebral ischemia, acute
dynamic cardiovascular changes, lacunar infarcts, microbleeds

1

See reviews of the literature including references 3–5.
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